This article is more than 5 years old. Information may no longer be current.
TIF controls chronic GERD symptoms through 4 years
Click Here to Manage Email Alerts
Transoral incisionless fundoplication with the EsophyX device provided long-term control of GERD symptoms through 4 years of follow-up, according to new data from the TEMPO trial presented at Minimally Invasive Surgery Week, the Society of Laparoendoscopic Surgeons 2017 annual meeting.
Transoral incisionless fundoplication using the EsophyX device (EndoGastric Solutions) reconstructs the gastroesophageal valve to restore barrier function and prevent reflux.
“This new 4-year analysis represents an important clinical milestone for patients who no longer benefit from PPI therapy and are seeking lasting relief from chronic GERD symptoms,” Karim S. Trad, MD, clinical professor of surgery at George Washington University School of Medicine, said in a press release. “The results of this comprehensive study confirm the endoscopic TIF 2.0 procedure as a durable alternative to PPIs and more invasive anti-reflux surgery operations.”
Between June and August 2012, Trad and colleagues randomly assigned 63 patients with chronic GERD symptoms to undergo either TIF (n = 40) or PPI therapy (n = 23), and after 6 months all 21 remaining PPI patients elected to cross over and undergo TIF.
The study met all its primary endpoints, according to the press release. Overall, 89% of patients reported they no longer experienced regurgitation, and 87% reported all their atypical symptoms were eliminated 4 years after the procedure.
“The recent data from this multi-center study reaffirms the existing clinical evidence that supports the TIF 2.0 procedure as an effective long-term treatment option for patients who suffer from GERD symptoms despite the use of PPIs,” Skip Baldino, President and CEO of EndoGastric Solutions, said in the press release.
Disclosures: Trad reports he received honoraria from EndoGastric Solutions. Baldino is employed by EndoGastric Solutions.